The ADVANCING ACCESS® patient assistance program is committed to helping patients afford their Gilead medication, including:

  • Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide); Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Descovy® (emtricitabine/tenofovir alafenamide); Emtriva® (emtricitabine); Genvoya® (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide); Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide ); Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate); Truvada® (emtricitabine/tenofovir disoproxil fumarate); Tybost® (cobicistat); Vemlidy®(tenofovir alafenamide); Viread® (tenofovir disoproxil fumarate)

Advancing Access provides assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program offerings for patients include:

  • Access to call center associates who can help patients and their providers with insurance-related questions, including providing information regarding coverage options.
  • Provides co-pay assistance for eligible patients who need assistance paying for out-of-pocket medication costs. Not valid for patients enrolled in government healthcare prescription drug programs, such as Medicare Part D and Medicaid. Patients in the coverage gap known as the "donut hole" also are not eligible.
  • The Advancing Access patient assistance program provides Gilead medications at no charge for eligible patients with no other insurance options.

Information about how to apply for any of these forms of assistance can be found at www.GileadAdvancingAccess.com or by calling 1-800-226-2056 between 9:00 a.m. and 8:00 p.m. (Eastern).

Truvada for Pre-Exposure Prophylaxis

Gilead is committed to ensuring that individuals at risk of HIV have access to Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) tablets. We support comprehensive payer coverage and maintain the Gilead Advancing Access program for qualified individuals in the United States who cannot afford their medications. This includes our Truvada for PrEP co-pay assistance program for commercially insured individuals, and the Medication Assistance Program (MAP), which provides free medication for those who qualify based on financial need.

As insurance plans change, out-of-pocket costs for some individuals may have increased. To ensure we are addressing the affordability challenges, Gilead regularly evaluates its support programs for individuals at risk of HIV who are either considering or taking Truvada for PrEP.

We are pleased to announce two enhancements to the Gilead Advancing Access program:

  • Effective September 1, 2018, Gilead will increase its annual benefit for Truvada from up to $4,800 to $7,200. This increase will apply to both Truvada for PrEP and Truvada for chronic HIV treatment as part of a complete three-drug regimen. Enrollment terms and conditions will remain the same. Gilead’s co-pay coupon program is not available for patients enrolled in any state or federally funded prescription drug program, such as Medicare Part D and Medicaid.
  • Effective July 1, 2018, individuals who qualify for the MAP will be eligible for 12 months rather than six months. This change will make it easier for individuals to enroll and remain in the program.

We encourage anyone facing affordability challenges in accessing Truvada for PrEP to phone (800) 226-2056 to speak to an Advancing Access counselor directly or visit www.gileadadvancingaccess.com to learn more about the program, including the financial support that may be available for Truvada for PrEP.